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Abstract: 
Objective: Several studies suggest that thyroid hormones may affect erythropoiesis. However the mechanism by which thyroid 
hormones alter the ferritin concentration is not well known. Therefore, the present case-control study was designed to determine the 
changes due to hyperthyroidism in serum ferritin, iron and transferrin levels and to investigate the inter-relationship between these 
parameters. 
Material: This study was conducted on 50 newly diagnosed hyperthyroid patients and the results were compared with 50 age and sex 
matched healthy controls. Serum ferritin was assessed by two site sandwich immunoassay using direct chemiluminometric technology. 
TIBC and serum iron were estimated by colorimetric method. 
Results: Serum ferritin (314.43 ± 68.7 ng/mL) and iron concentration (159.88 ± 36.28 µg/dL) were found to be increased in 
hyperthyroid patients as compared to healthy controls (255.23 ± 45.5 ng/mL and 110.52 ± 20.52 µg/dL respectively). There was a 
significant difference between hyperthyroid patients and healthy controls in serum levels of ferritin and iron (p<0.05 for both). Serum 
ferritin and iron were correlated significantly positive with thyroid parameters while a significant negative correlation was found with 
transferrin. 
Conclusion: Our data suggest that alterations in thyroid status in a given individual produce significant changes in serum ferritin, iron 
and transferrin levels. Increased ferritin levels seem to be protective against increased oxidative stress seen in hyperthyroidism but these 
also increase atherosclerotic risk. However, a large scale study is recommended to establish the fact. 
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Introduction 
Thyroid hormone, 3, 3’, 5-triiodo-L-thyronine (T3) has an important role to play in eukaryotic cell development, 
differentiation and metabolism. Hyperthyroidism occurs when there is increased secretion of hormones over a 
short or long period of time. The symptoms of hyperthyroidism include increased excitability, intolerance to heat, 
increased perspiration, mild to extreme weight loss, varying degrees of diarrhea, muscle weakness, anxiety or 
psychic disorders, extreme fatigue, lack of sleep and tremors of the hands [1].  
Several minerals and trace elements like iodine, iron, selenium and zinc are essential for normal thyroid 
hormone metabolism. Iron is an essential nutrient and a potential toxin. It is physiologically essential for growth 
and survival, playing important roles in many biological processes, such as electron and oxygen transport, and 
DNA replication. However, free iron can be toxic to cells due to the ability of iron to catalyze free radical 
formation that can destroy lipid membranes and other cellular constituents. Intracellular iron homeostasis is mainly 
controlled by cytoplasmic iron response proteins (IRP1 and IRP2), which are known as iron-sensing proteins [2].  
Plasma ferritin is a measure of iron stores and the best single test to confirm iron deficiency. It is also a marker of 
some neoplastic diseases. It has been reported in literature that thyroid hormones may affect erythropoiesis. 
Transferrin is a plasma glycoprotein for iron delivery which is expressed in all mammals and is synthesized in the 
liver. Serum ferritin levels have been observed to be altered in patients with hyperthyroidism. Some studies have 
reported increased ferritin levels while others observed these levels to be decreased. Also, the mechanism by which 
thyroid hormones alter the ferritin concentration is not well known [3-6]. Therefore, the present case-control study 
was designed to determine the changes due to hyperthyroidism in serum ferritin, iron and transferrin levels and to 
investigate the interrelationship between these parameters.  
Material and methods 
This study was conducted on 50 newly diagnosed hyperthyroid patients and 50 healthy controls with thyroid 
profile in the normal range. None of the patients had anemia, liver diseases, malignancy, or inflammatory illness 
during the study period. All individuals suffering from chronic diseases, such as diabetes mellitus, diseases of the 
liver, kidney, cardiac and other endocrine and immunological disorders were excluded from both patient groups 
and healthy controls with the help of suitable investigations. 
After obtaining informed consent from the subjects venous blood was collected from median anti cubital vein 
aseptically. Serum was separated and stored at -20 °C until analysis. Serum total triiodothyronine (TT3) and total 
thyroxine (TT4) levels were estimated by radioimmunoassay and TSH (thyroid stimulating hormone) levels were 
estimated by immunoradiometric assay (IRMA) to group them as normal subjects and hyperthyroid patients. 
Serum-free triiodothyronine (FT3) and free thyroxine (FT4) were assayed by a chemiluminescent assay method 
using Advia Centaur CP analyzer with original kits obtained from Siemens healthcare diagnostics Ltd. (Bayswater 
Victoria, Australia). Serum ferritin levels were analysed on chemiluminescence using Siemens kits. The ADVIA 
Centaur CP Ferritin assay is a two site sandwich immunoassay using direct chemiluminometric technology, which 
uses constant amounts of two anti ferritin antibodies. The first antibody, in the lite reagent is a polyclonal goat anti 
ferritin antibody labeled with acridinium ester. The second antibody, in the solid phase is a monoclonal mouse 
antiferritin antibody, which is covalently coupled to paramagnetic particles [7]. Total iron binding capacity (TIBC) 
was analysed by colorimetric method with precipitation using kits of Giesse diagnostics srl (Colle Presentio, Rome, 
 Verma M et al. American Journal of Cancer Therapy and Pharmacology 2014, 2:56-63 
  
Ivy Union Publishing | http: //www.ivyunion.org December 15, 2014 | Volume 2  
Page 3 of 8 
Italy). The iron carrier protein transferrin is saturated with the addition of trivalent iron ions. The unbound iron is 
removed by precipitation with basic carbonate of magnesium and supernatant tied to the iron dose is the total iron 
binding capacity [8]. Serum iron was estimated by colorimetric method using kits of Giesse diagnostics srl (Colle 
Presentio, Rome, Italy). Transferrin bound iron is released at an acid pH in serum. Fe (III) and Fe (II) react with 
chromazurol B(2,6-dichloro-4-hydroxy-3,3-dimethylfuchsone-5,5-dicarboxylic acid) and the 
cetyltrimethylammonium bromide (CTMA), forming a ternary blue colour complex. The intensity of colour is 
proportional to sample iron concentration [9]. Free transferrin levels were then calculated using the formulae 
(Transferrin = TIBC-serum iron) [7]. Erythrocytic parameter analyses were done by hemocytometry.  
Normal ranges of different parameters used in the study are as following: TSH (0.3-5.0 µIU/mL), TT3 (70-200 
ng/dL), TT4 (5.5-13.5 µg/dL), FT3 (2.3-4.2 pg/mL), FT4 (0.89-1.76 ng/dL), ferritin (22-322 ng/mL in males and 
10-291 ng/mL in females), TIBC (250-420 mg/dL), iron (60-150 µg/dL in males and 40-145 µg/dL in females) 
and transferrin (150-340 mg/dL). 
All statistical analysis was performed using the IBM Statistical Package for the Social Sciences (SPSS) version 
20 for windows. Values shown in the text, tables and figures are mean ±SD. Student t test was applied for 
comparison of means of study groups. p value < 0.05 was considered significant. Correlations between groups 
were analyzed using Pearson correlation coefficient (r) formula. 
Results 
The mean age of the patients in hyperthyroid group was 48.45 ± 12.35 (20-65) years, while in control group was 
45.14 ± 10.8 (20-63) years. Out of 50 patients, 7 were males and 43 were females in hyperthyroid group while 
there were 5 males and 45 females in control group. The biochemical parameters are shown in table 1. BMI (body 
mass index) was found to be slightly lower in hyperthyroid patients (27.34 ± 0.78 kg/m2) as compared to controls 
(31.25 ± 0.84 kg/m2; p<0.001). Our results revealed that TT3, TT4, FT3 and FT4 levels were significantly elevated 
while TSH levels were significantly decreased in hyperthyroid patients. Serum ferritin (314.43 ± 68.7 ng/mL) and 
iron concentration (159.88 ± 36.28 µg/dL) was found to be increased in hyperthyroid patients as compared to 
healthy controls (255.23 ± 45.5 ng/mL and 110.52 ± 20.52 µg/dL respectively). There was a significant difference 
between hyperthyroid patients and healthy controls in serum levels of ferritin and iron (p<0.05 for both). Ferritin 
levels were correlated significantly positive with FT3 (r = 0.200, p = 0.032; Fig. 1). A positive correlation was 
found with iron (r = 0.021, p = 0.922) and negative with transferrin levels (r = -0.069, p = 0.742) but the correlation 
was not significant statistically. Serum iron was correlated negatively with TSH (r = -0.440, p = 0.028; Fig. 2) and 
serum transferrin levels (r = -0.853, p = 0.000) and the correlation was statistically significant. Transferrin levels 
were correlated positively and statistically significantly with TSH (r = 0.448, p = 0.025; Fig. 3). 
Discussion 
The results of present study showed an increased level of serum ferritin and iron while decreased levels of 
transferrin in hyperthyroid patients. Increase in serum ferritin levels in patients with hyperthyroidism may be due 
to the direct action of thyroid hormones on its synthesis and release [4]. However, the molecular mechanisms 
involved in the hepatic regulation of ferritin expression by T3 remain to be determined. These results are in 
accordance with other studies which also showed an increased level of serum ferritin in hyperthyroid patients [5, 6]. 
Serum ferritin has been widely accepted as an acute-phase reactant (any substance in blood which increases in 
response to an acute condition such as infection, injury, inflammation etc.) and is nonspecifically elevated in a wide 
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variety of inflammatory states including infection, malignancy, and autoimmune diseases [10, 11]. This could be 
one of the reasons for increased ferritin levels.   
 
 
 
Table 1 Biochemical parameters of hyperthyroid patients and healthy controls 
 
 
Parameter Healthy controls Hyperthyroid patients p value 
Number 50 50 - 
Age 45.14 ± 10.8 48.45 ± 12.35 0.5 
BMI (kg/m2) 23.25 ± 0.84 21.34 ± 0.78 0.03* 
Hb (g/dL) 14.05 ± 6.66 12.73 ± 0.35 0.02* 
Hematocrit (ratio%) 42.94 ± 0.83 39.21 ± 1.50 0.03* 
TT3 (ng/dL) 131.08 ± 22.52 249.24 ± 63.80 0.000** 
TT4 (μg/dL) 7.98 ± 2.32 13.15 ± 5.67 0.009* 
TSH (μIU/mL) 1.67 ± 1.77 0.10 ± 0.01 0.000** 
FT3 (pg/mL) 3.67 ± 1.11 5.53±3.93 0.001* 
FT4 (ng/dL) 1.64 ± 0.98 2.17±1.78 0.001* 
Ferritin (ng/mL) 255.23 ± 45.5 314.43 ± 68.7 0.004* 
TIBC (mg/dL) 350.55 ± 36.6 237.98 ± 24.33 0.02* 
Serum iron (µg/dL) 110.52 ± 20.52 159.88 ± 36.28 0.005* 
Transferrin (mg/dL) 240.03 ± 16.1 78.09 ± 46.18 0.02* 
*Significant; **Highly significant; all values are in mean ± SD.  
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Figure 1 Scatter diagram showing correlation of serum ferritin with FT3 in cases (r = 0.200, p = 0.032). 
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Figure 2 Figure showing correlation of TSH with serum iron in cases (r = -0.440, p = 0.028). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Scatter diagram showing correlation of TSH with serum transferrin in cases (r = 0.448, p = 0.025). 
 
In relation to thyroid hormone and ferritin, many controversial reports are available in literature. It has been 
observed in one study that thyroidectomy induced hypothyroidism was associated with increased rat hepatic 
ferritin content, which may be because of post-transcriptional changes in the ferritin synthetic rate [1, 12, 13]. 
Since, there is controversy regarding effect of thyroid hormones on ferritin levels, post-surgical state being 
responsible for these findings cannot be ruled out in this case. Also, administration of T3 to hypothyroid 
individuals produced a significant increase in the serum ferritin level supporting our findings [3]. More recently, 
hyperthyroid rats with elevated T3 and T4 levels were found to have 38% increased liver ferritin protein synthesis 
rate over controls [1].  
We previously reported that total iron content was increased in patients of hyperthyroidism; although the origin 
of increased iron content could not be established. Some evidence suggests that ferritin plays a role not only in iron 
storage but also in iron transport, probably because of its carrying capacity of 4500 iron atoms compared with 
transferrin's carrying capacity of only 2 per transferrin. Thus, increase in iron can be due to an elevated level of 
serum ferritin [3].  
Thyroperoxidase (TPO) is an iron-containing enzyme that initiates the first two steps in thyroid hormone 
synthesis [14]. In thyrotoxicosis, activity of this enzyme is increased, so more iron will be required for its proper 
action which may lead to increased ferritin. As it is well known that when iron levels are low, ferritin synthesis is 
decreased; similarly, when iron levels are high, ferritin synthesis increases [15]. It has long been known that iron is 
involved in the translational regulation of ferritin and it has been shown in a study that the initiation of synthesis of 
ferritin can be reversibly inhibited by removing iron from the culture medium with the iron chelator deferoxamine 
[16]. Thyroid hormone stimulates erythropoeisis. This is attributed to direct hormonal effect on the erythroid 
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marrow and to increased erythropoietin secretion leading to increased iron turnover [17] Findings of the present 
study may be consequent to increased iron turnover. 
Ferritin occurs in two forms, H- and L-ferritin. H-ferritin is known to reduce iron-induced oxidative stress by 
capturing and decreasing intracellular free iron. So, increased ferritin in hyperthyroidism could play a role in 
protection from oxidative damage. Previous studies have shown the presence of oxidative stress in hyperthyroid 
patients [18]. Ferritin H chain is transcriptionally regulated by oxidative stress [19, 20]. The increase in ferritin 
synthesis is mediated by heme oxygenase (HO), an enzyme induced by oxidative stress that liberates iron from 
heme. This may lead to increased iron. The released iron stimulates ferritin synthesis through the IRE–IRP 
machinery and the newly synthesized ferritin reduces the amount of iron available for reactive oxygen species 
(ROS) production and cellular damage. So, increased ferritin synthesis may be closely associated with protection 
against iron-induced oxidative stress [2].  
Transferrin is synthesized in the liver. It is a plasma glycoprotein which is expressed in all mammals and it 
helps in iron transport. The low concentration of transferrin appears to reflect the increased iron stores. In 
addition, transferrin is a negative acute phase protein (protein whose concentration decreases in response to acute 
phase reaction like in inflammation) which leads to its decreased concentration in hyperthyroidism. 
Hyperthyroidism is an oxidative stress like condition causing damage to transferrin by neutrophil-derived 
superoxide which leads to protein fragmentation and increased ferrous iron release [11] leading to increase in 
iron and decrease in transferrin levels as depicted from present study also. 
Serum ferritin levels are assumed to be an atherosclerotic risk factor. Salonen et al. demonstrated that a ferritin 
concentration ≥200 μg/L was associated with a 2.2-fold increase in the risk of acute myocardial infarction in men 
[21].  Iron catalyzes the formation of reactive oxygen species through the Fenton and Haber–Weiss reactions. Free 
radicals cause lipid peroxidation, leading to the modification of LDL at the molecular level, facilitating its 
deposition and leading to the formation of atherosclerotic plaque [22, 23]. Thus, increased ferritin levels enhance 
oxidation of LDL increasing cardiovascular abnormalities. Transferrin is one of the most important antioxidant. 
Apotransferrin, at physiological concentrations, is known to inhibit lipid peroxidation in the liposome model by 
iron-binding [11]. But decreased level of transferrin in study population is also pointing towards increased 
cardiovascular risk factor. So, increased ferritin and iron along with decreased transferring levels in 
hyperthyroidism increase the overall cardiovascular risk.  Further investigations are required to confirm this 
observation. 
Conclusion 
Our data suggests that alterations in thyroid status in a given individual produce changes in serum ferritin, iron 
and transferrin levels. Increased ferritin levels seem to be protective against increased oxidative stress seen in 
hyperthyroidism but, at the same time, changes in other parameters may point towards atherosclerotic risk also.  
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